Development challenges solved
The scientific, regulatory and operational barriers that have kept plant-derived compounds from pharmaceutical-grade consistency, and which engine resolves each one.
Engine One
Botanical Stability & Targeted Delivery
Chemical integrity, comparability, and delivery.
Molecular integrity degrades over time
Preserves molecular structure at the source, maintaining compositional integrity across time and conditions.
Storage, transport, and handling cause loss
Mitigates environmental stressors so chemical degradation does not accumulate across the distribution chain.
Compositional drift between batches and sites
Establishes a consistent molecular baseline, limiting drift and improving batch-to-batch consistency.
Results do not reproduce across institutions
Structurally consistent inputs allow reproducible results across studies, sites, and research environments.
Plant-derived inputs are inherently variable
Standardizes biological variability into consistent, usable inputs suitable for development and scale.
Dosing behavior shifts across batches and time
Uniform composition supports consistent dosing behavior across batches and extended timeframes.
Absorption and performance vary unpredictably
Reduced compositional variability produces more consistent absorption and performance outcomes.
Targeted delivery is unreliable
Creates the conditions precision requires, so compounds are delivered predictably without chemical modification.
Variability delays timelines and forces rework
Fewer variability-related failures means less rework, lower batch rejection, and shorter development cycles.
Engine Two
Botanical Integrity, Provenance & Traceability
Identity, provenance, anti-counterfeiting, and enforcement.
Counterfeit and substituted material enters the chain
Verifies the compound by its own chemical signature, so a correct label on the wrong material does not pass.
Excise and taxation cannot be enforced on unverified goods
Material-level identity gives regulators and authorities a basis for assessment that packaging records cannot provide.
Diversion and tampering go undetected between handoffs
Non-destructive re-verification at any custody point surfaces substitution and tampering as review triggers.
Origin and authenticity cannot be verified
Establishes continuous, auditable records of origin and composition at every lifecycle stage.
Traceability breaks across partners and jurisdictions
Standardized tracking holds across systems, partners, and global jurisdictions.
Lifecycle data is fragmented between systems
Unifies lifecycle data into one continuous, auditable record, closing the gaps between handoffs.
Handling and storage conditions go undocumented
Captures complete lifecycle documentation, giving continuous visibility into handling conditions.
Programs cannot be compared to one another
Standardized lifecycle data enables direct comparability across institutions, studies, and programs.
Audit documentation is assembled after the fact
Structured, audit-ready records are produced as the product moves, not reconstructed under review.
Cross-border compliance is inconsistent
Standardized documentation and traceability support multinational compliance.
Technology transfer between facilities is slow
Comparable, well-documented materials improve transferability across facilities and development partners.
Both engines, integrated
What the two engines resolve only together.
Meeting pharmaceutical-grade standards for plant-derived compounds
Together they let compounds meet expectations for reproducibility, comparability, and lifecycle integrity.
Validation burden in development and approval
Reduced variability plus documented continuity lowers revalidation requirements and complexity.
Scaling consistently across global systems
Consistent material performance and maintained lifecycle continuity across every market.
Preserving integrity from research through commercialization
Compositional integrity holds and lifecycle continuity is unbroken from discovery to market.
Request technical materials
Detailed validation data, methodology and platform architecture are available to qualified partners under a confidentiality agreement.
Platform questions
Yes. Each is independently deployable and licenses on its own. Engine One can be licensed for a drug development program alone. Engine Two can be deployed across manufacturing, distribution and regulated supply chains alone.
Integrated, they cover both what a product does and what it is. Engine One reduces the variability that undermines performance, Engine Two removes the doubt about identity and origin, and together they hold consistency from formulation through end use.
Internal validation has demonstrated preservation of compound integrity under degradation-inducing conditions, improved consistency in pharmacokinetic-related outcomes, reliable detection of controlled inconsistencies, and repeatable system behavior across varied test conditions.
Detailed technical information, validation data, and platform architecture are available under appropriate confidentiality agreements. Use the Contact page to request access.